NASDAQ | VICL: 2.45  -0.03
investors
Investors

News Releases

DateSubject
December 11, 2008 Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
December 9, 2008 SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
December 3, 2008 Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7® in Turkey
December 1, 2008 Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
November 21, 2008 Vical Announces Strategic Restructuring and Staff Reduction
November 17, 2008 Vical Executive Alain Rolland Named AAPS Fellow
November 12, 2008 Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
November 6, 2008 U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin® Adjuvant
November 5, 2008 Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Program
November 4, 2008 Vical to Present at Upcoming Investor Conferences
October 29, 2008 Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
October 23, 2008 Vical to Present at Upcoming Investor Conferences
October 8, 2008 Vical Expands Applications of Vaxfectin® Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
October 7, 2008 Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
September 15, 2008 Vical to Present at UBS Global Life Sciences Conference
August 21, 2008 Vaxfectin®-formulated Measles DNA Vaccine Could Address Unmet Need for Infants
August 19, 2008 Karolinska Institutet to Test Vical’s Vaxfectin® Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
August 5, 2008 Vical Reports Second Quarter and First Six Months 2008 Financial Results and Highlights in Product Development Programs
July 29, 2008 Vical Announces News Release and Conference Call Schedule for Second Quarter 2008 Financial Results
July 22, 2008 Vical Receives $1 Million Milestone Payment From AnGes MG for Angiogenesis Program
July 17, 2008 Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
July 14, 2008 Vical to Present Phase 1 Data for Vaxfectin®-Formulated Pandemic Influenza DNA Vaccines
June 25, 2008 Vical Advances RapidResponse™ DNA Vaccine Platform Under $6 Million Grant from NIH
June 16, 2008 Vical Pandemic Influenza Vaccines Provide Complete Protection in Animal Studies; The Journal of Infectious Diseases Publishes H5N1 Challenge Data
June 12, 2008 Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7® Phase 3 Trial
June 5, 2008 Promise of Vical's CMV Vaccine Noted by Independent Experts
June 4, 2008 Vical to Present at Needham & Company Biotechnology and Medical Technology Conference
May 12, 2008 Vical to Present at Upcoming Investor Conferences
May 8, 2008 Vical Reports First Quarter 2008 Financial Results and Updates Key Development Programs
May 1, 2008 Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
April 23, 2008 Vical Promotes Melanoma Awareness Month With Allovectin-7® Video Report
April 3, 2008 Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
March 28, 2008 Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
March 12, 2008 Vical to Present at Cowen and Company Health Care Conference
March 4, 2008 Vical to Present at BIO and BVGH Global Health Partnering Event
February 21, 2008 Vical Reports 2007 Financial Results and Progress in Product Development Programs
February 14, 2008 Vical Announces News Release and Conference Call Schedule for 2007 Financial Results
February 5, 2008 Vical to Present at BIO CEO and Investor Conference
January 22, 2008 Vical Expands Portfolio of CMV Vaccine Technologies Through License Agreement With The Wistar Institute
January 17, 2008 Vical Receives Payment from AnGes MG for Allovectin-7® Phase 3 Pivotal Trial
January 7, 2008 Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference

AnGes Ebola Antibody Therapy

P. 858 646 1100 10390 Pacific Center Court, San Diego, California 92121
Designed by Mentus
This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.